PPMD’s Cardiac Initiative
PPMD has an ongoing commitment to cardiac care, because the heart is a muscle too.
Heart issues don’t just affect some people with Duchenne; they affect ALL people with Duchenne. While advances in respiratory care have improved respiratory outcomes, dilated cardiomyopathy and heart failure remain the leading cause of death in Duchenne.
Just as there are variations in onset of skeletal muscle difficulties, there are variations in the onset of cardiac muscle difficulties. Eventually, nearly 100% of all people with Duchenne develop dilated cardiomyopathy and heart failure. Cardiomyopathy is also a potential risk for mothers and daughters who are carriers.
For the past several years, PPMD has heavily invested in the pursuit of optimal care, interventions, and research pertaining to the management and prevention of cardiomyopathy and has invested close to $5 million in this pursuit.
We have learned so much, but there is still a tremendous amount to do to understand and improve heart health in people with Duchenne. For this reason, PPMD is committed to continuing to bring together experts to understand cardiac needs and opportunities; further exploring novel cardiac treatments; and understanding more about device and transplant interventions.
Cardiac research has received a significant amount of funding over the past several years, and PPMD is actively supporting current and new initiatives in identifying new cardiac drugs and repurposing existing drugs to treat cardiomyopathy.
Cardiac Video Library
As part of PPMD’s Cardiac Initiative, we presented a four-part webinar series on cardiac care.